Published in J Cell Biol on December 14, 2009
Wapl is an essential regulator of chromatin structure and chromosome segregation. Nature (2013) 1.92
Inhibition of CDK4/6 protects against radiation-induced intestinal injury in mice. J Clin Invest (2016) 1.43
Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks. Cancer Res (2013) 1.20
Mre11 regulates CtIP-dependent double-strand break repair by interaction with CDK2. Nat Struct Mol Biol (2012) 1.10
Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Ther Targets (2010) 1.10
Akt/PKB suppresses DNA damage processing and checkpoint activation in late G2. J Cell Biol (2010) 1.08
DNA damage response is suppressed by the high cyclin-dependent kinase 1 activity in mitotic mammalian cells. J Biol Chem (2011) 0.97
Chemical genetics reveals a specific requirement for Cdk2 activity in the DNA damage response and identifies Nbs1 as a Cdk2 substrate in human cells. PLoS Genet (2012) 0.92
MicroRNAs in skin response to UV radiation. Curr Drug Targets (2013) 0.88
CDK-mediated RNF4 phosphorylation regulates homologous recombination in S-phase. Nucleic Acids Res (2015) 0.86
MLL1 is essential for the senescence-associated secretory phenotype. Genes Dev (2016) 0.85
Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis. Cell Div (2013) 0.83
CDK2 and PKA mediated-sequential phosphorylation is critical for p19INK4d function in the DNA damage response. PLoS One (2012) 0.83
Focal adhesion kinase antagonizes doxorubicin cardiotoxicity via p21(Cip1.). J Mol Cell Cardiol (2013) 0.81
Viral cyclins mediate separate phases of infection by integrating functions of distinct mammalian cyclins. PLoS Pathog (2012) 0.81
Working hard for recovery: mitotic kinases in the DNA damage checkpoint. Cell Biosci (2013) 0.79
Multiple protein kinases influence the redistribution of fission yeast Clp1/Cdc14 phosphatase upon genotoxic stress. Mol Biol Cell (2012) 0.79
Paraquat modulates alternative pre-mRNA splicing by modifying the intracellular distribution of SRPK2. PLoS One (2013) 0.79
R-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repair. Mol Cancer (2010) 0.78
CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis. J Clin Invest (2014) 0.76
Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells. Sci Rep (2017) 0.75
Honokiol as a Radiosensitizing Agent for Colorectal cancers. Curr Colorectal Cancer Rep (2013) 0.75
Residual Cdk1/2 activity after DNA damage promotes senescence. Aging Cell (2017) 0.75
BRCA1 recruitment to damaged DNA sites is dependent on CDK9. Cell Cycle (2017) 0.75
Insulin-Like Growth Factor-1-Mediated DNA Repair in Irradiated Salivary Glands Is Sirtuin-1 Dependent. J Dent Res (2016) 0.75
ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science (2007) 20.11
Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol (1999) 16.81
The DNA damage response: ten years after. Mol Cell (2007) 11.80
Human CtIP promotes DNA end resection. Nature (2007) 10.63
E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev (2002) 10.06
ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol (2005) 8.27
Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature (2005) 7.45
DNA end resection, homologous recombination and DNA damage checkpoint activation require CDK1. Nature (2004) 6.94
Mammalian cyclin-dependent kinases. Trends Biochem Sci (2005) 5.54
The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J (1999) 5.44
A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci. Mol Cell (2004) 5.29
Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol (2008) 5.10
DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-terminal domains. Mol Cell Biol (2004) 4.78
Rapid destruction of human Cdc25A in response to DNA damage. Science (2000) 4.74
Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol (2001) 4.35
Cdk1 is sufficient to drive the mammalian cell cycle. Nature (2007) 4.26
CDK targets Sae2 to control DNA-end resection and homologous recombination. Nature (2008) 3.96
The CDK regulates repair of double-strand breaks by homologous recombination during the cell cycle. EMBO J (2004) 3.87
Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat Cell Biol (2005) 3.65
Human CtIP mediates cell cycle control of DNA end resection and double strand break repair. J Biol Chem (2009) 3.24
Cyclin-dependent kinases and cell-cycle transitions: does one fit all? Nat Rev Mol Cell Biol (2008) 2.48
Global chromatin compaction limits the strength of the DNA damage response. J Cell Biol (2007) 2.40
Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. DNA Repair (Amst) (2004) 2.39
Cdc2-cyclin B kinase activity links Crb2 and Rqh1-topoisomerase III. Genes Dev (2002) 2.37
ATM regulates ATR chromatin loading in response to DNA double-strand breaks. J Exp Med (2006) 2.31
Srs2 DNA helicase is involved in checkpoint response and its regulation requires a functional Mec1-dependent pathway and Cdk1 activity. EMBO J (2000) 2.15
Cell-cycle-dependent and ATM-independent expression of human Chk1 kinase. Oncogene (1999) 1.68
An essential role for Cdk1 in S phase control is revealed via chemical genetics in vertebrate cells. J Cell Biol (2007) 1.65
p21 Inhibits Cdk1 in the absence of Cdk2 to maintain the G1/S phase DNA damage checkpoint. Mol Biol Cell (2007) 1.54
A role for the phosphorylation of hRad9 in checkpoint signaling. J Biol Chem (2003) 1.42
BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site. Mol Cell Biol (1999) 1.29
Cyclin-dependent kinase 2 dependent phosphorylation of ATRIP regulates the G2-M checkpoint response to DNA damage. Cancer Res (2007) 1.27
Induction versus progression of brain tumor development: differential functions for the pRB- and p53-targeting domains of simian virus 40 T antigen. Mol Cell Biol (1994) 1.26
Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response. Cancer Res (2005) 1.25
Phosphorylation of ATR-interacting protein on Ser239 mediates an interaction with breast-ovarian cancer susceptibility 1 and checkpoint function. Cancer Res (2007) 1.06
Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer (2009) 11.25
Tumour biology: senescence in premalignant tumours. Nature (2005) 10.15
RAS oncogenes: the first 30 years. Nat Rev Cancer (2003) 8.61
Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell (2007) 8.47
Mammalian cyclin-dependent kinases. Trends Biochem Sci (2005) 5.54
Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell (2003) 5.17
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet (2003) 4.74
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell (2004) 4.39
Cdk1 is sufficient to drive the mammalian cell cycle. Nature (2007) 4.26
A pericyte origin of spinal cord scar tissue. Science (2011) 4.12
A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell (2010) 3.97
The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84
Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta (2002) 3.77
p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet (2007) 3.30
Increased telomere fragility and fusions resulting from TRF1 deficiency lead to degenerative pathologies and increased cancer in mice. Genes Dev (2009) 2.91
EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.59
Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell (2011) 2.56
Cell cycle kinases in cancer. Curr Opin Genet Dev (2007) 2.46
c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell (2011) 2.28
Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol (2009) 1.99
CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci (2007) 1.95
Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc Natl Acad Sci U S A (2006) 1.93
What we have learned about pancreatic cancer from mouse models. Gastroenterology (2012) 1.78
Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell (2005) 1.78
Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J (2010) 1.66
Genetic rescue of Cdk4 null mice restores pancreatic beta-cell proliferation but not homeostatic cell number. Oncogene (2003) 1.62
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55
DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS. Nat Struct Mol Biol (2010) 1.49
Paleobiology and comparative morphology of a late Neandertal sample from El Sidron, Asturias, Spain. Proc Natl Acad Sci U S A (2006) 1.48
Concurrent deletion of cyclin E1 and cyclin-dependent kinase 2 in hepatocytes inhibits DNA replication and liver regeneration in mice. Hepatology (2013) 1.48
Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol Cell (2011) 1.44
A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition. J Clin Invest (2008) 1.38
Cyclin-dependent kinase inhibitor p21 controls adult neural stem cell expansion by regulating Sox2 gene expression. Cell Stem Cell (2012) 1.33
Cdk4 promotes adipogenesis through PPARgamma activation. Cell Metab (2005) 1.31
Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. Cancer Cell (2005) 1.23
The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma. J Pathol (2009) 1.22
Genetically engineered mouse models of pancreatic adenocarcinoma. Mol Oncol (2013) 1.15
Genetic evidence for patrilocal mating behavior among Neandertal groups. Proc Natl Acad Sci U S A (2010) 1.12
Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma. Proc Natl Acad Sci U S A (2013) 1.11
Neanderthal medics? Evidence for food, cooking, and medicinal plants entrapped in dental calculus. Naturwissenschaften (2012) 1.08
Is Cyclin D1-CDK4 kinase a bona fide cancer target? Cancer Cell (2006) 1.08
Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion. EMBO J (2012) 1.08
Spontaneous and UV radiation-induced multiple metastatic melanomas in Cdk4R24C/R24C/TPras mice. Cancer Res (2006) 1.03
Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome. Proc Natl Acad Sci U S A (2011) 1.02
Mice thrive without Cdk4 and Cdk2. Mol Oncol (2007) 1.02
Toll-like receptor-4 (TLR4) down-regulates microRNA-107, increasing macrophage adhesion via cyclin-dependent kinase 6. J Biol Chem (2011) 1.01
Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity. Cancer Res (2005) 0.96
Driving the cell cycle to cancer. Adv Exp Med Biol (2003) 0.93
Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation. Am J Pathol (2006) 0.91
Loss of nuclear receptor RXRα in epidermal keratinocytes promotes the formation of Cdk4-activated invasive melanomas. Pigment Cell Melanoma Res (2010) 0.88
Cdk6-dependent regulation of G(1) length controls adult neurogenesis. Stem Cells (2011) 0.88
Postnatal Schwann cell proliferation but not myelination is strictly and uniquely dependent on cyclin-dependent kinase 4 (cdk4). Mol Cell Neurosci (2007) 0.87
Late-replicating CNVs as a source of new genes. Biol Open (2013) 0.84
Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas. PLoS One (2013) 0.82
Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR. Bioorg Med Chem Lett (2012) 0.81
Reversible, interrelated mRNA and miRNA expression patterns in the transcriptome of Rasless fibroblasts: functional and mechanistic implications. BMC Genomics (2013) 0.80
Using cells devoid of RAS proteins as tools for drug discovery. Mol Carcinog (2009) 0.79
Emergence and evolutionary analysis of the human DDR network: implications in comparative genomics and downstream analyses. Mol Biol Evol (2014) 0.78
Cdk7: open questions beyond the prevailing model. Cell Cycle (2012) 0.78
Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor. Bioorg Med Chem Lett (2012) 0.78
Evaluation of genetic melanoma vaccines in cdk4-mutant mice provides evidence for immunological tolerance against authochthonous melanomas in the skin. Int J Cancer (2006) 0.76
Mouse models of cancer. Mol Oncol (2013) 0.76
Genetic characterization of the role of the Cip/Kip family of proteins as cyclin-dependent kinase inhibitors and assembly factors. Mol Cell Biol (2014) 0.76
Brief communication: Subvertical grooves on interproximal wear facets from the El Sidrón (Asturias, Spain) Neandertal dental sample. Am J Phys Anthropol (2011) 0.75
Late-replicating CNVs as a source of new genes. Biol Open (2014) 0.75
Mariano Barbacid: director of Spain's first national cancer centre. Interviewed by Adrian Burton. Lancet Oncol (2002) 0.75